These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25649349)

  • 1. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.
    ; Voronin Y; Zinszner H; Karg C; Brooks K; Coombs R; Hural J; Holt R; Fast P; Allen M
    Vaccine; 2015 Mar; 33(10):1243-9. PubMed ID: 25649349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.
    Cooper CJ; Metch B; Dragavon J; Coombs RW; Baden LR;
    JAMA; 2010 Jul; 304(3):275-83. PubMed ID: 20639561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced HIV seropositivity: a problem on the rise.
    Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
    J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
    Penezina O; Krueger NX; Rodriguez-Chavez IR; Busch MP; Hural J; Kim JH; O'Connell RJ; Hunter E; Aboud S; Higgins K; Kovalenko V; Clapham D; Crane D; Levin AE;
    Clin Vaccine Immunol; 2014 Mar; 21(3):391-8. PubMed ID: 24403525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines.
    Schwartz DH; Mazumdar A; Winston S; Harkonen S
    Clin Diagn Lab Immunol; 1995 May; 2(3):268-71. PubMed ID: 7664169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
    Khurana S; Needham J; Park S; Mathieson B; Busch MP; Nemo G; Nyambi P; Zolla-Pazner S; Laal S; Mulenga J; Chomba E; Hunter E; Allen S; McIntyre J; Hewlett I; Lee S; Tang S; Cowan E; Beyrer C; Altfeld M; Yu XG; Tounkara A; Koita O; Kamali A; Nguyen N; Graham BS; Todd D; Mugenyi P; Anzala O; Sanders E; Ketter N; Fast P; Golding H
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):304-12. PubMed ID: 17019363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of prophylactic vaccines against HIV-1.
    Schiffner T; Sattentau QJ; Dorrell L
    Retrovirology; 2013 Jul; 10():72. PubMed ID: 23866844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
    Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.
    Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR
    J Virol; 2019 May; 93(10):. PubMed ID: 30842326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
    J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tests produced by Organon Teknika for the diagnosis of antibodies to HIV-1 and HIV-2.
    Chantrain C
    Przegl Epidemiol; 1992; 46(1-2):3-10. PubMed ID: 1475387
    [No Abstract]   [Full Text] [Related]  

  • 16. Preparation and characterization of human HIV type 1 neutralizing reference sera.
    Vujcic LK; Quinnan GV
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):783-7. PubMed ID: 7546904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Diagnostics and Vaccines: It Takes Two to Tango.
    Colón W; Oriol-Mathieu V; Hural J; Hattingh L; Adungo F; Lagatie O; Lavreys L; Allen M; Anzala O; Espy N; Fransen K; Garcia PJ; Maciel M; Murtagh M; Peel SA; Peeling RW; Tan LLJ; Warren M; Pau MG; D'Souza PM
    J Infect Dis; 2024 Jun; 229(6):1919-1925. PubMed ID: 38451247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion.
    Farzadegan H; Henrard DR; Kleeberger CA; Schrager L; Kirby AJ; Saah AJ; Rinaldo CR; O'Gorman M; Detels R; Taylor E; Phair JP; Margolick JB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):448-55. PubMed ID: 8970472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers.
    Silbermann B; Tod M; Desaint C; Pialoux G; Petitprez K; Slama L; Poncelet H; Moreau C; Mazarin V; Heshmati F; Salmon-Ceron D; Guillet JG; Launay O
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1445-8. PubMed ID: 19000023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.